Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
How heart failure risk rises after surgery
Wed June 29th - The development of atrial fibrillation following surgery is an important risk factor for heart failure, researchers report today. More
Brain surgery benefits intracranial pressure
Wed June 29th - Craniectomy for intracranial hypertension offers significant benefit, according to new guidance, triggered by British research. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Row over new extra time drug ban

Thursday February 2nd, 2012

A row broke out today over proposals to restrict a drug for male cancer that was discovered in the UK.

Abiraterone has been found to extend the lives of patients with incurable prostate cancer and can be taken as pills at home.

But the National Institute for Health and Clinical Excellence says it is too expensive - and is proposing to advise the NHS against using it.

The drug was discovered by Cancer Research UK scientists and the organisation hit out angrily yesterday.

Chief clinician Professor Peter Johnson said the proposal made "no sense".

He said: "Since it became available in the UK, abiraterone has been one of the most requested treatments from the Cancer Drugs Fund.

"This is because patients and doctors value the extra months of life it can give if prostate cancer has come back after chemotherapy.

“We need to find a way for it to be routinely available through the NHS. At the moment it is too expensive and NICE must find a better way to ensure drugs that are already working for patients get approved."

About 3,300 men a year could be prescribed the drug - although NICE says this could increase to more than 5,000. NICE says using the drug would cost more than £63,000 for every good quality year of life (QALY) it saved.

The drug normally costs £3,000 a month.

Cancer Research UK chief executive Dr Harpal Kumar said: “We’re hugely frustrated that NICE felt the drug wasn’t good value for money.

"Generous public donations to Cancer Research UK and other organisations paid for the initial development of the drug and we feel extremely let down that the drug’s manufacturer couldn’t offer NICE a price they could agree on."

And Owen Sharp, chief executive of the Prostate Cancer Charity, said: "Sadly, this draft decision sends yet another clear message to men that investing in treatments for prostate cancer is simply not a priority for the NHS.

"Men, running out of time and often desperately trying to access this drug, are currently being forced into a postcode lottery, where decisions on whether they are given a further chance at life are made based on where they live in the UK."

But NICE chief executive Sir Andrew Dillon said he was "disappointed" it could not back the drug.

He said: "It is an expensive drug and the independent advisory committee that made this decision did not feel the drug provided enough benefit to patients to justify the price the NHS is being asked to pay, even with the discount that the manufacturer has offered."

Tags: Cancer | Menís Health | Pharmaceuticals | UK News

Printer friendly page Printer friendly page